Cost-Utility Analysis of Planned Early Delivery or Expectant Management for Late Preterm Pre-eclampsia (PHOENIX)

Overview

Journal Pharmacoecon Open

Date 2022 Jul 21

PMID 35861912

Authors

Rachael Hunter

Alice Beardmore-Gray

Melanie Greenland

Louise Linsell

Edmund Juszczak

Pollyanna Hardy

Anna Placzek

Andrew Shennan

Neil Marlow

Lucy C Chappell

Affiliations

Soon will be listed here.

Abstract

Aim: There is currently limited evidence on the costs associated with late preterm pre-eclampsia beyond antenatal care and post-natal discharge from hospital. The aim of this analysis is to evaluate the 24-month cost-utility of planned delivery for women with late preterm pre-eclampsia at 34-36 weeks' gestation compared to expectant management from an English National Health Service perspective using participant-level data from the PHOENIX trial.

Methods: Women between 34 and 36 weeks' gestation in 46 maternity units in England and Wales were individually randomised to planned delivery or expectant management. Resource use was collected from hospital records between randomisation and primary hospital discharge following birth. Women were followed up at 6 months and 24 months following birth and self-reported resource use for themselves and their infant(s) covering the previous 6 months. Women completed the EQ-5D 5L at randomisation and follow-up.

Results: A total of 450 women were randomised to planned delivery, 451 to expectant management: 187 and 170 women, respectively, had complete data at 24 months. Planned delivery resulted in a significantly lower mean cost per woman and infant(s) over 24 months (- £2711, 95% confidence interval (CI) - 4840 to - 637), with a mean incremental difference in QALYs of 0.019 (95% CI - 0.039 to 0.063). Short-term and 24-month infant costs were not significantly different between the intervention arms. There is a 99% probability that planned delivery is cost-effective at all thresholds below £37,000 per QALY gained.

Conclusion: There is a high probability that planned delivery is cost-effective compared to expectant management. These results need to be considered alongside clinical outcomes and in the wider context of maternity care.

Trial Registration: ISRCTN registry ISRCTN01879376. Registered 25 November 2013.

Citing Articles

A Systematic Review of Methods and Practice for Integrating Maternal, Fetal, and Child Health Outcomes, and Family Spillover Effects into Cost-Utility Analyses.

Lamsal R, Yeh E, Pullenayegum E, Ungar W Pharmacoeconomics. 2024; 42(8):843-863.

PMID: 38819718 PMC: 11249496. DOI: 10.1007/s40273-024-01397-5.

Planned delivery or expectant management for late preterm pre-eclampsia in low-income and middle-income countries (CRADLE-4): a multicentre, open-label, randomised controlled trial.

Beardmore-Gray A, Vousden N, Seed P, Vwalika B, Chinkoyo S, Sichone V Lancet. 2023; 402(10399):386-396.

PMID: 37393919 PMC: 11667733. DOI: 10.1016/S0140-6736(23)00688-8.

Planned delivery for pre-eclampsia between 34 and 37 weeks of gestation: the PHOENIX RCT.

Chappell L, Brocklehurst P, Green M, Hardy P, Hunter R, Beardmore-Gray A Health Technol Assess. 2022; .

PMID: 36547875 PMC: 10068586. DOI: 10.3310/CWWH0622.

References

Chappell L, Brocklehurst P, Green M, Hunter R, Hardy P, Juszczak E . Planned early delivery or expectant management for late preterm pre-eclampsia (PHOENIX): a randomised controlled trial. Lancet. 2019; 394(10204):1181-1190. PMC: 6892281. DOI: 10.1016/S0140-6736(19)31963-4. View

Petrou S, Krabuanrat N, Khan K . Preference-Based Health-Related Quality of Life Outcomes Associated with Preterm Birth: A Systematic Review and Meta-analysis. Pharmacoeconomics. 2019; 38(4):357-373. DOI: 10.1007/s40273-019-00865-7. View

Petrou S, Yiu H, Kwon J . Economic consequences of preterm birth: a systematic review of the recent literature (2009-2017). Arch Dis Child. 2018; 104(5):456-465. DOI: 10.1136/archdischild-2018-315778. View

Khan K, Petrou S, Dritsaki M, Johnson S, Manktelow B, Draper E . Economic costs associated with moderate and late preterm birth: a prospective population-based study. BJOG. 2015; 122(11):1495-505. DOI: 10.1111/1471-0528.13515. View

von Dadelszen P, Payne B, Li J, Ansermino J, Broughton Pipkin F, Cote A . Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet. 2010; 377(9761):219-27. DOI: 10.1016/S0140-6736(10)61351-7. View

Tan M, Wright D, Syngelaki A, Akolekar R, Cicero S, Janga D . Comparison of diagnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE. Ultrasound Obstet Gynecol. 2018; 51(6):743-750. DOI: 10.1002/uog.19039. View

Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D . Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011; 20(10):1727-36. PMC: 3220807. DOI: 10.1007/s11136-011-9903-x. View

Faria R, Gomes M, Epstein D, White I . A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials. Pharmacoeconomics. 2014; 32(12):1157-70. PMC: 4244574. DOI: 10.1007/s40273-014-0193-3. View

Jabrayilov R, Vermeulen K, Detzel P, Dainelli L, van Asselt A, Krabbe P . Valuing Health Status in the First Year of Life: The Infant Health-Related Quality of Life Instrument. Value Health. 2019; 22(6):721-727. DOI: 10.1016/j.jval.2018.12.009. View

10.

Johnson S, Marlow N, Wolke D, Davidson L, Marston L, OHare A . Validation of a parent report measure of cognitive development in very preterm infants. Dev Med Child Neurol. 2004; 46(6):389-97. DOI: 10.1017/s0012162204000635. View

11.

Chappell L, Green M, Marlow N, Sandall J, Hunter R, Robson S . Planned delivery or expectant management for late preterm pre-eclampsia: study protocol for a randomised controlled trial (PHOENIX trial). Trials. 2019; 20(1):85. PMC: 6350286. DOI: 10.1186/s13063-018-3150-1. View

12.

Korvenranta E, Linna M, Rautava L, Andersson S, Gissler M, Hallman M . Hospital costs and quality of life during 4 years after very preterm birth. Arch Pediatr Adolesc Med. 2010; 164(7):657-63. DOI: 10.1001/archpediatrics.2010.99. View

13.

Stevens W, Shih T, Incerti D, Ton T, Lee H, Peneva D . Short-term costs of preeclampsia to the United States health care system. Am J Obstet Gynecol. 2017; 217(3):237-248.e16. DOI: 10.1016/j.ajog.2017.04.032. View

14.

Fox A, McHugh S, Browne J, Kenny L, Fitzgerald A, Khashan A . Estimating the Cost of Preeclampsia in the Healthcare System: Cross-Sectional Study Using Data From SCOPE Study (Screening for Pregnancy End Points). Hypertension. 2017; 70(6):1243-1249. DOI: 10.1161/HYPERTENSIONAHA.117.09499. View

15.

. Computerised interpretation of fetal heart rate during labour (INFANT): a randomised controlled trial. Lancet. 2017; 389(10080):1719-1729. PMC: 5413601. DOI: 10.1016/S0140-6736(17)30568-8. View

16.

Duhig K, Seed P, Myers J, Bahl R, Bambridge G, Barnfield S . Placental growth factor testing for suspected pre-eclampsia: a cost-effectiveness analysis. BJOG. 2019; 126(11):1390-1398. PMC: 6771855. DOI: 10.1111/1471-0528.15855. View

17.

Say L, Chou D, Gemmill A, Tuncalp O, Moller A, Daniels J . Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014; 2(6):e323-33. DOI: 10.1016/S2214-109X(14)70227-X. View

18.

van Hout B, Janssen M, Feng Y, Kohlmann T, Busschbach J, Golicki D . Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012; 15(5):708-15. DOI: 10.1016/j.jval.2012.02.008. View

19.

van Baaren G, Broekhuijsen K, van Pampus M, Ganzevoort W, Sikkema J, Woiski M . An economic analysis of immediate delivery and expectant monitoring in women with hypertensive disorders of pregnancy, between 34 and 37 weeks of gestation (HYPITAT-II). BJOG. 2016; 124(3):453-461. DOI: 10.1111/1471-0528.13957. View

20.

Beardmore-Gray A, Greenland M, Linsell L, Juszczak E, Hardy P, Placzek A . Two-year follow-up of infant and maternal outcomes after planned early delivery or expectant management for late preterm pre-eclampsia (PHOENIX): A randomised controlled trial. BJOG. 2022; 129(10):1654-1663. PMC: 9545311. DOI: 10.1111/1471-0528.17167. View